Filtered By:
Source: Current Pharmaceutical Design
Condition: Fatty Liver Disease (FLD)

This page shows you your search results in order of date.

Order by Relevance | Date

Total 2 results found since Jan 2013.

Serum uric acid and diabetes: from pathophysiology to cardiovascular disease.
Abstract Hyperuricemia, has been traditionally related to nephrolithiasis and gout. However, it has also been associated with the development of type 2 diabetes mellitus (T2DM) and cardiometabolic and cardiovascular diseases. Pathophysiologically, elevated serum uric acid (SUA) levels may be associated with abnormal lipid and glucose metabolism. In this narrative review, we consider the associations between hyperuricemia, hyperglycemia, atherosclerosis and thrombosis. Furthermore, we comment on the available evidence linking elevated SUA levels with the incidence and outcomes of coronary heart disease, stroke, per...
Source: Current Pharmaceutical Design - January 4, 2021 Category: Drugs & Pharmacology Authors: Katsiki N, Dimitriadis GD, Mikhailidis DP Tags: Curr Pharm Des Source Type: research

The Role of Statins in the Treatment of Type 2 Diabetes Mellitus: an Update.
Abstract The prevalence of type 2 diabetes mellitus (T2DM) is increasing worldwide. T2DM is associated with both microvascular (neuropathy, nephropathy and retinopathy) and macrovascular complications [coronary artery disease (CAD), stroke, carotid artery disease and peripheral artery disease (PAD)]. Apart from acting on diabetic dyslipidemia, statins were shown to exert beneficial effects on several diabetic complications as well as other cardiovascular (CVD) risk predictors such as endothelial dysfunction, inflammation, oxidative stress, chronic kidney disease (CKD), non-alcoholic fatty liver disease (NAFLD), me...
Source: Current Pharmaceutical Design - September 12, 2013 Category: Drugs & Pharmacology Authors: Niki Katsiki, Vasilios G Athyros, Asterios Karagiannis, Dimitri P Mikhailidis Tags: Curr Pharm Des Source Type: research